Search BRITE hierarchies

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
  L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
    L01 ANTINEOPLASTIC AGENTS
      L01E PROTEIN KINASE INHIBITORS
        L01EA BCR-ABL tyrosine kinase inhibitors [DG:DG03161]
          L01EA04 Bosutinib [DG:DG00718]
            D09728  Bosutinib hydrate (JAN) <JP/US>

USP drug classification [BR:br08302]
  Antineoplastics
    Molecular Target Inhibitors
      Bosutinib [DG:DG00718]
        D09728  Bosutinib hydrate (JAN)

Therapeutic category of drugs in Japan [BR:br08301]
  4  Agents affecting cellular function
    42  Antineoplastics
      429  Miscellaneous
        4291  Other Antitumors
          D09728  Bosutinib hydrate (JAN)

Drug groups [BR:br08330]
  Antineoplastic
    DG01918  Tyrosine kinase inhibitor
      DG03161  BCR-ABL inhibitor
        DG00718  Bosutinib
          D09728  Bosutinib hydrate
  Metabolizing enzyme substrate
    DG01633  CYP3A/CYP3A4 substrate
      DG02913  CYP3A4 substrate
        DG00718  Bosutinib
          D09728  Bosutinib hydrate

Drug classes [BR:br08332]
  Antineoplastic
    DG03161  BCR-ABL inhibitor
      D09728  Bosutinib hydrate

Target-based classification of drugs [BR:br08310]
  Protein kinases
    Non-receptor tyrosine kinases
      SRC family
        SRC [HSA:6714] [KO:K05704]
          D09728  Bosutinib hydrate (JAN) <JP/US>
      ABL family
        BCR-ABL [HSA_VAR:25v1] [HSA:25] [KO:K06619]
          D09728  Bosutinib hydrate (JAN) <JP/US>

New drug approvals in the USA [br08319.html]
  D09728

New drug approvals in Europe [br08329.html]
  D09728

New drug approvals in Japan [br08318.html]
  D09728

New drug approvals in the USA, Europe and Japan [br08328.html]
  D09728

Drug metabolizing enzymes and transporters [br08309.html]
  D09728

Pharmacogenomic biomarkers [br08341.html]
  D09728